NCT07450287 2026-03-04
CardioNETPOL
National Institute of Cardiology, Warsaw, Poland
Not yet recruiting
Clinical Trials
14 trialsNCT07366658 2026-01-26
NEUK203-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT07102056 2025-12-29
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
First Affiliated Hospital of Zhejiang University
Not yet recruiting
NCT07258810 2025-12-02
ETP-NET
Hospices Civils de Lyon
Not yet recruiting
NCT07165132 2025-09-10
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Not yet recruiting
NCT07014254 2025-06-10
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
Xijing Hospital
Phase NA Not yet recruiting
NCT06764368 2025-01-08
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
Phase 2 Not yet recruiting
NCT06607198 2024-09-23
PitNET2024
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT06485739 2024-07-03
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06300216 2024-03-08
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Qilu Hospital of Shandong University
Not yet recruiting
NCT04889742 2023-12-26
HETERERO
Charite University, Berlin, Germany
Phase 2 Not yet recruiting
NCT05967481 2023-08-01
Evaluation of Study Experiences of Neuroendocrine Tumor Patients
Power Life Sciences Inc.
Not yet recruiting
NCT05894486 2023-06-08
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Phase 2 Not yet recruiting
NCT04788927 2023-04-07
PPGL-Pred
Rigshospitalet, Denmark
Not yet recruiting